A major study investigating the effectiveness of liver perfusion as a technique to improve the function of donor livers that would have otherwise been rejected has shown that up to 7 in every 10 could be used after just 4-6 hours of the assessment.
The study, ‘Transplantation of discarded livers following viability testing with normothermic machine perfusion’, published today in Nature Communications, could have significant implications for the liver transplant waiting list and the commissioning of local transplant services.
Currently, across the UK, a third of donated livers don’t meet desired transplant criteria and aren’t used. Chronic liver disease in the UK is rising annually, a result of obesity and increasing alcohol misuse causing approximately 8500 deaths per year. For those with end-stage liver disease, a transplant is the only hope for survival, but demand for livers suitable for transplantation far outstrips supply. According to the latest NHS Blood and Transplant report, up to 20% of people awaiting a transplant operation died or were removed from waiting lists due to ill health.
A growing proportion of donated livers are coming from high-risk donors with a history of alcohol misuse, obesity or elderly people with comorbidities, often when a patient has suffered cardiac arrest that is unexpected and when the patient cannot or should not be resuscitated. These livers are of lower quality and pose risks to recipients. Consequently, the majority are not transplanted.
Funded by the Wellcome Trust, experts from the University of Birmingham’s Centre for Liver and Gastrointestinal Research, University Hospitals Birmingham NHS Foundation Trust and the NIHR Birmingham Biomedical Research Centre have found that just 4-6 hours of normothermic machine perfusion assessment enabled 70 per cent of currently discarded livers to recover enough to allow successful transplantation into a recipient.
Mr Hynek Mergental, Honorary Senior Lecturer at the University of Birmingham and Consultant Surgeon at the UHB Liver Unit said: “Whilst liver transplantation is one of the most advanced surgical procedures, up to now, there has been no objective mean to assess suitability of donor livers for transplantation. The VITTAL trial validated our pre-clinical research and pilot clinical observations and these viability criteria can now guide transplant teams worldwide to provide access to the life-saving transplantation to more patients in need. “
VITTAL project lead, Professor Darius Mirza, Consultant Transplant Surgeon at University Hospitals Birmingham NHS Foundation Trust and Honorary Professor at the University of Birmingham, added: “This challenging study was designed to assess function of discarded livers in the real-life situation, using the normothermic machine perfusion. The major challenge in this pioneering clinical trial was to assure patients safety while pushing the envelope of sub-optimal liver utilisation.”
Mr Thamara Perera, Consultant Transplant Surgeon at UHB explains: “This ground breaking trial has proven that objective parameters can be used for making a decision to use a borderline liver. The observed 100% study participants post-transplant survival was reassuring and provided our patients and the surgical team with confidence to implement and further expand this approach, which now helps the sickest patients on our waiting list to underwent transplantation sooner and safer.”
Dr Simon Afford, Reader in Liver Immunobiology at the of the University of Birmingham’s Institute of Immunology and Immunotherapy, said: “It has long been recognised that as a consequence of our population aging the quality of donated livers keeps declining. Based on our latest discoveries we believe that in the near future the machine perfusion platform will facilitate therapeutic interventions to improve liver viability. We expect we will be able salvage even more organs than 70% observed in the VITTAL trial, including livers from donors with known alcohol misuse or obesity.”
Tim Knott, Head of Innovation Programmes at the Wellcome Trust, said: “Many more patients who need liver transplants will benefit from this technology. Giving surgeons the tools to assess if a liver transplant will be viable will help the thousands of people who have chronic liver disease globally.”
John Forsythe, Medical Director of Organ Donation and Transplantation for NHS Blood and Transplant, said: “New techniques of Organ perfusion and preservation are a vital developing area of organ donation and transplantation. We are delighted that a number of doctors and scientists in the UK are leading the way in this field of research.
“Each year a small number of donated organs are not transplanted for a variety of reasons. Transplant success relies on a significant amount of activity taking place in a short space of time. New techniques are already allowing us to transplant donated organs that would not have been possible in the past. More research in this area is likely to increase that ability.”
For more information please contact Sophie Belcher, Communications Manager, University of Birmingham, on +44 07815607157. Alternatively, contact the Press Office out of hours on +44 (0)7789 921165.
University Hospitals Birmingham NHS Foundation Trust runs the Queen Elizabeth Hospital Birmingham, Birmingham Chest Clinic, Heartlands Hospital, Good Hope Hospital, Solihull Hospital and various community services across the region.
The Trust has regional centres for trauma, burns, plastics, neurosciences, dermatology and cancer. It also has centres of excellence for vascular, bariatric and pathology services, as well as the treatment of MRSA and other infectious diseases. We also have expertise in HIV/AIDS, premature baby care, bone marrow transplants and thoracic surgery.
UHB has the largest solid organ transplantation programme in Europe and runs Umbrella, the sexual health service for Birmingham and Solihull. It is also home to the West Midlands Adult Cystic Fibrosis Centre and a nationally-renowned weight management clinic and research centre.
The Queen Elizabeth Hospital Birmingham is a Major Trauma Centre treating the most severely injured casualties from across the region. The hospital’s single site 100-bed critical care unit is the largest in Europe.
The Trust hosts the Institute of Translational Medicine (ITM) and led the West Midlands Genomics Medicine Centre as part of the national 100,000 Genomes Project.
UHB is also proud to host the Royal Centre for Defence Medicine (RCDM) at the Queen Elizabeth Hospital Birmingham. The RCDM provides dedicated training for defence personnel and is a focus for medical research.
About the NIHR
The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:
- Funds, supports and delivers high quality research that benefits the NHS, public health and social care
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR supports applied health research for the direct and primary benefit of people in low- and middle-income countries, using UK aid from the UK government.
This work uses data provided by patients and collected by the NHS as part of their care and support and would not have been possible without access to this data. The NIHR recognises and values the role of patient data, securely accessed and stored, both in underpinning and leading to improvements in research and care. www.nihr.ac.uk/patientdata